|
Marketing authorization holder for Xepi is the Spanish company, Ferrer ... dazu passt noch folgendes aus dem letzten Monat: Luqa and Ferrer to collaborate in China Shanghai's Luqa Pharmaceuticals has reached a deal with Spanish drugmaker Ferrer Internacional to develop and commercialize ozenoxacin in China and Hong Kong. Branded variously as Ozanex, Dubine and Xepi, the product is an antibiotic treatment for the highly infectious skin disease impetigo, approved in the USA, Canada and 11 countries in Europe. The firms will work together to seek approval in China, building on a strategic collaboration agreed in October 2018 related to the development of products from the Ferrer pipeline. https://www.thepharmaletter.com/in-brief/brief-luqa-and-ferr… |
|
| aus der Diskussion: | Biofrontera - Heiße Turnaround-Spekulation |
| Autor (Datum des Eintrages): | Caldo (30.05.19 20:48:14) |
| Beitrag: | 49,039 von 66,519 (ID:60701231) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |